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PPARDiabetes is the leading cause of end-stage renal disease in developed countries. In spite of excellent glucose
and blood pressure control, including administration of angiotensin converting enzyme inhibitors and/or
angiotensin II receptor blockers, diabetic nephropathy still develops and progresses. The development of
additional protective therapeutic interventions is, therefore, a major priority. Nuclear hormone receptors
regulate carbohydrate metabolism, lipid metabolism, the immune response, and inﬂammation. These
receptors also modulate the development of ﬁbrosis. As a result of their diverse biological effects, nuclear
hormone receptors have become major pharmaceutical targets for the treatment of metabolic diseases. The
increasing prevalence of diabetic nephropathy has led intense investigation into the role that nuclear
hormone receptors may have in slowing or preventing the progression of renal disease. This role of nuclear
hormone receptors would be associated with improvements in metabolism, the immune response, and
inﬂammation. Several nuclear receptor activating ligands (agonists) have been shown to have a renal
protective effect in the context of diabetic nephropathy. This review will discuss the evidence regarding the
beneﬁcial effects of the activation of several nuclear, especially the vitamin D receptor (VDR), farnesoid X
receptor (FXR), and peroxisome-proliferator-associated receptors (PPARs) in preventing the progression of
diabetic nephropathy and describe how the discovery and development of compounds that modulate the
activity of nuclear hormone receptors may provide potential additional therapeutic approaches in the
management of diabetic nephropathy. This article is part of a Special Issue entitled: Translating nuclear
receptors from health to disease.slating nuclear receptors from
x C281, Aurora, CO 80045, USA.
.V.Published by Elsevier B.V.1. Introduction
Diabetes mellitus is the most common cause of end-stage renal
disease in the developed world requiring dialysis or renal transplan-
tation for the maintenance of life. The pathogenesis of diabetic
nephropathy is multifactorial. Hypertension, abnormal carbohydrate
metabolism, abnormal lipid metabolism, accumulation of lipids,
upregulation of proﬁbrotic growth factors (including, renin, angio-
tensin II, transforming growth factor β [TGF-β] and vascular
endothelial growth factor [VEGF]), upregulation of proinﬂammatory
cytokines (including, nuclear factor kappa B [NF-κB], CCL2, also known
as MCP1, tumor necrosis factor [TNF] and interleukin 1β [IL-1β]),
increased oxidative stress, and increased production of advanced
glycation end products all have an important role in the pathogenesis
and progression of diabetic nephropathy [1–4].
In spite of all the beneﬁcial interventions implemented in patients
with diabetes, including tight glucose control, tight blood pressurecontrol, and angiotensin II receptor antagonism, renal injury progresses
inmost of thesepatients.Additional treatmentmodalities thatmodulate
the pathogenetic pathways involved in diabetic nephropathy are
urgently needed to slow the progression of renal failure in patients
with diabetes.
Studies in humans with type 1 or type 2 diabetes mellitus and in
animal models of these diseases have reported an accumulation of
lipids (triglycerides and cholesterol) in the kidney—even in the
absence of abnormalities in serum lipid levels—which is associated
with the development of glomerulosclerosis, tubulointerstitial ﬁbro-
sis, and the progression of diabetic renal disease [5–13]. The
accumulation of triglycerides and cholesterol in the kidney is
mediated by increased expression and activity of the transcriptional
factors the sterol regulatory element binding proteins 1 and 2 [SREBP-
1 and SREBP-2] which are master regulators of fatty acid and
cholesterol synthesis. We have therefore become interested in nuclear
receptors that are potential negative regulators of SREBPs and also
inﬂammation, oxidative stress, and ﬁbrosis and therefore may slow
down the progression of diabetic kidney disease.
This review discusses nuclear hormone receptors thought to have a
role in the pathogenesis of kidney disease, especially diabetic
nephropathy, including the vitamin D receptor (VDR), farnesoid X
receptor (FXR), and peroxisome-proliferator-associated receptors
(PPARs).
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VitaminD3 is acquired either fromdietary sources or is generated via
solar ultraviolet irradiation of 7-dehydrocholesterol in the skin. Vitamin
D3 is then processed into the active hormone, 1,25 dihydroxyvitamin
D3 (1,25(OH)2D3), via two consecutive hydroxylation reactions [14,15].
The ﬁrst such reaction takes place in the liver and is catalyzed by 25-
hydroxylase and the second is catalyzed by 1α-hydroxylase, which is
expressed predominantly in the kidney. Extrarenal 1,25(OH)2D3 can
also be produced locally in a number of cell types that express VDR,
notably cells of the skin, immune system, colon, pancreas, and
vasculature. Locally produced 1,25(OH)2D3 does not contribute signif-
icantly to circulating 1,25(OH)2D3 levels, but it retains the capacity to be
active in the cells and tissues where they are produced.
The activity of 1,25(OH)2D3 is mediated by VDR. 1,25(OH)2D3–VDR
has multiple physiological and pathological roles that extend beyond
the regulation of mineral metabolism, including the regulation of renal
and cardiovascular functions. Naturally occurring, low-afﬁnity VDR
ligands that have been identiﬁed over the past 2 years (for example,
lithocholic acid, curcumin, and polyunsaturated fatty acids)may trigger
1,25(OH)2D3-independent activationofVDR in speciﬁc tissues [16]. 1,25
(OH)2D3 can also induce rapid nongenomic effects on target cells in the
vitamin D endocrine system regulated by vitamin D.
Although VDR may not be involved in this pathway as rapid
actions of 1,25-(OH)2D3 can be elicited in the absence of VDR, the
nongenomic pathway regulated by 1,25(OH)2D3 can interact with
genomic pathway to modulate VDR-dependent gene expression [17].
1,25(OH)2D3 rapid activation of cytosolic kinases via nongenomic
pathway has been shown to lead to the phosphorylation of critical co-
activators of VDR, resulting in modulation of VDR-dependent gene
transcription [17]. VDR may also exert direct effects on the nucleus
and form complexes with the p65 subunit of NFκB and thus cause
repression of p65-mediated gene transcription. This expression
inhibition results in an anti-inﬂammatory effect [18].
Immunohistochemical studies indicate that VDR is expressed in
proximal and distal tubular epithelial cells, glomerular parietal
epithelial cells, and collecting duct cells; VDR is also expressed by
cultured podocytes and mesangial cells [19–21].
A link between the development of type 1 diabetes mellitus and
vitamin D deﬁciency has been well described, and a 2008 meta-
analysis of ﬁve observational studies suggested that children who
receive vitamin D supplementation have a reduced risk of developing
type 1 diabetes mellitus [22]. Over the past 5 years, a number of large
observational studies have also suggested an association between the
onset of type 2 diabetes mellitus and vitamin D deﬁciency [23].
Vitamin D deﬁciency is also very common in patients with chronic
kidney disease (CKD), perhaps in part because diabetes is the most
common cause of CKD [24,25].
VDR agonists have been shown to be protective in mouse models
of diabetes mellitus. The studies in mice with type 1 diabetes mellitus
and type 2 diabetes mellitus have shown that the renal protective
effects of VDR agonists are mediated by inhibition or antagonism of
the renin angiotensin system [26–31] and NF-κB [18,20,32] which are
major mediators of increased intraglomerular pressure, podocyte
damage, oxidative stress, inﬂammation, and ﬁbrosis. In addition, VDR
agonists activate hepatocytes growth factor and prevent renal
interstitial myoﬁbroblast activation [33,34]. In contrast, VDR knockout
mice have been shown to be more susceptible to streptozotocin
induced diabetic kidney disease in part via activation of the renin
angiotensin system [35]. In this regard, VDR agonists in combination
therapywith an angiotensin converting enzyme inhibitor (ACEI) or an
angiotensin II type 1 receptor blocker (ARB) have synergistic effects in
development of kidney disease in rats with subtotal nephrectomy [36]
and in mice with diabetes [37–39].
Recently we investigated if treatment of mice with diet induced
obesity (DIO) and insulin resistance with the vitamin D receptor (VDR)agonist doxercalciferol (1α-hydroxyvitaminD2) prevents renal disease.
DIO and insulin resistance in mice is associated with proteinuria, renal
mesangial expansion, accumulationof extracellularmatrix proteins, and
activation of oxidative stress, proinﬂammatory cytokines, proﬁbrotic
growth factors, and the sterol regulatory element binding proteins,
SREBP-1 and SREBP-2 that mediate increases in fatty acid and
cholesterol synthesis [12]. Kidney VDR expression was decreased in
the DIO mice and treatment with doxercalciferol increased VDR
expression in the kidney. Our results indicate that treatment of DIO
mice with the VDR agonist decreases proteinuria, podocyte injury,
mesangial expansion, and extracellular matrix protein accumulation.
The VDR agonist also decreases macrophage inﬁltration, oxidative
stress, proinﬂammatory cytokines and proﬁbrotic growth factors.
Furthermore the VDR agonist also prevents the activation of the renin
angiotensin aldosterone system including the angiotensin II type 1
receptor (AT1R) and themineralocorticoid receptor (MR). Anadditional
novel ﬁnding of our study is that activation of VDR results in decreased
accumulation of neutral lipids (triglycerides and cholesterol) and
expression of adipophilin in the kidney by decreasing SREBP-1 and
SREBP-2 expression and target enzymes that mediate fatty acid and
cholesterol synthesis [40].
Treatment of DIO mice with doxercalciferol also increased the
expressionof thebile acid activatednuclear hormone receptor farnesoid
X receptor (FXR) and bile acid activated G protein coupled receptor
TGR5. Previous studies have indicated that bile acids activate VDR
[41,42]. Recent studies also indicate that VDR agonists can increase
portal bile acid concentration and trigger FXR like effects in the liver and
the intestine in rats [43]. In further support of our ﬁndings VDR
knockout mice have decreased FXR expression in the ileum, and
treatment of mice with calcitriol increased FGF15 expression in the
ileum which is a known FXR target [44]. Clearly our results warrant
further investigation into how these two nuclear receptors cross-talk.
VDR agonists also play a protective role in several non-diabetic
models of renal disease, including in mice and rats with Heyman
nephritis [45], anti-thy-1 model of mesangial proliferative glomerulo-
nephritis [46–48], subtotal nephrectomy [49–51], puromycin amino-
glycoside induced podocyte damage [52] and unilateral ureteral
obstruction [53].
VDR agonists have also been shown to decrease proteinuria in
human subjects with chronic kidney disease [54–56] and IgA nephrop-
athy [57], and improve survival in patients with late stage ESRD [58]. A
recent large scale randomized controlled study (VITAL) in patients with
type 2 diabetes mellitus who were already been treated with ACE
inhibitors of ARBs showed that treatment with paricalcitol resulted in a
signiﬁcant reduction in urinary albumin [59]. These studies therefore
indicate that in addition to animal models of obesity, insulin resistance,
and diabetes, VDR agonists are also highly beneﬁcial in human subjects
with diabetic or non-diabetic kidney disease.
3. Farnesoid X receptor
FXR is an adopted orphan nuclear receptor named after farnesol,
an intermediate in the mevalonate biosynthetic pathway, which was
found to weakly activate FXR at supraphysiological concentrations
[60,61]. Subsequently endogenous bile acids were found to bind to
and activate FXR and FXR was found to have a critical role in the
regulation of bile-acid metabolism [62–64]. The hydrophobic bile acid
chenodeoxycholic acid and its conjugated forms are the most potent
endogenous agonists of FXR, whereas the hydrophilic bile acids
ursodeoxycholic acid and muricholic acid do not activate this
receptor. Ligand-activated FXR can bind to and activate or repress
the transcription of a large number of genes either as an FXR–retinoid
X receptor (RXR) heterodimer or as a monomer [65].
FXR is highly expressed in the liver, intestine, adrenal gland, and
with particularly high expression in the kidney [66]. Activation of FXR
has an important role in maintaining glucose, lipid, and bile acid
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activation prevents rat liver ﬁbrosis induced with porcine serum or
bile duct ligation [69] FXR activation also prevents atherosclerosis in
LDL receptor knockout mice and ApoE knockout mice [70,71] and
vascular calciﬁcation on ApoE knockout mice with chronic kidney
disease [72].
GW4064 which was the ﬁrst synthetic high-afﬁnity, nonsteroidal
FXR agonist to be developed has been tested in rodent studies and
in vitro cell cultures [67,68]. However, the poor bioavailability of
GW4064 has limited its clinical development. The high-afﬁnity, semi-
synthetic, bile acid-derived FXR agonist, INT-747 (6α-ethyl-cheno-
deoxycholic acid) was subsequently developed and has exhibited
anticholestatic and antiﬁbrotic properties in rodent models of liver
disease [67]. A clinical trial is in progress to examine the physiological
effect of FXR activation by INT-747 in humans with nonalcoholic fatty
liver disease [67].
In mouse kidney, FXR has been detected in both isolated glomeruli
and proximal tubules. The expression level in proximal tubule cells is
much higher than in glomeruli [73]. In addition, FXR is expressed in
both cultured mouse mesangial cells and podocytes [73].
FXR (Nr1h4) knockout mice with streptozotocin-induced type 1
diabetes leads develop increased renal injury compared with wild-
type C57BL/6 mice with streptozotocin-induced type 1 diabetes [74].
These mice demonstrate increases in proteinuria, glomerulosclerosis,
tubulointerstitial ﬁbrosis, mesangial expansion, podocyte damage and
glomerular basement membrane thickening. There is also increased
macrophage inﬁltration, as well as increased expression of SREBP-1
and SREBP-2 that result in increased renal triglyceride and cholesterol
content.
In contrast treatment of db/db mice with type 2 diabetes [73], in
DBA/2J mice with diet-induced obesity and insulin resistance [75],
and DBA/2J mice with streptozotocin-induced type 1 diabetes [74]
with FXR agonists has marked renal protective effects. These
experimental models of diabetic nephropathy showed improvements
in proteinuria, glomerulosclerosis, tubulointerstitial ﬁbrosis, and
macrophage inﬁltration following treatment with FXR activating
agonists. These renal protective effects are mediated by effects on
lipid metabolism, oxidative stress, and on the production of proin-
ﬂammatory cytokines and proﬁbrotic growth factors [73,75]. FXR
agonists inhibit expression of SREBP-1 and carbohydrate response
element binding protein (ChREBP) in the kidney resulting in
decreased fatty acid synthesis and triglyceride accumulation [73–75].
FXR agonists also inhibit SREBP-2 resulting in decreased choles-
terol synthesis and accumulation in the kidney. These studies suggest
that FXR agonists can prevent the progression of kidney disease in
mouse models of type 1 diabetes mellitus, diet induced obesity and
insulin resistance, and type 2 diabetes mellitus.
4. Peroxisome-proliferator-associated receptors
Three PPAR subtypes (PPARα, PPARγ and PPARδ) have been
cloned and characterized; each is encoded by its own gene and each
has a unique tissue distribution [76].
4.1. Peroxisome-proliferator-associated receptor α
PPARα is predominantly expressed in the proximal tubules and in
the medullary thick ascending limb of Henle. Renal PPARα has an
important role in modulating energy utilization in the kidney through
the regulation of renal fatty-acid β-oxidation. The importance of this
role is made evident by the response of renal PPARα to dietary lipids
[77,78] and the protective effect of PPARα against ischemia/
reperfusion injury, in which the reduced renal fatty-acid oxidation
results in the accumulation of fatty acid and cellular toxicity
contributing to proximal tubule cell death [79,80]. PPARα activation
is also involved in the regulation of blood pressure through activationof the cytochrome P450 enzyme system in the proximal tubules [81].
Glomerular expression of PPARα was reported to be very low [82];
however, induction of PPARα expression has been observed in mouse
mesangial cells after stimulation with lipopolysaccharide—a process
which could contribute to the attenuation of lipopolysaccharide-
induced inﬂammatory responses [83]. A study in PPARα knockout
mice demonstrated that PPARα protects against glomerulonephritis
through its anti-inﬂammatory effects, which suggests that PPARα has
an important role in protection against glomerular disease [84].
Accumulating evidence suggests that modulation of PPARα activa-
tion could be beneﬁcial in the management of diabetic nephropathy.
PPARα knockoutmicewith streptozotocin-induced type1diabeticmice
have increased plasma free fatty acid and triglyceride levels and
enhanced diabetic nephropathy, as evidenced by increased mesangial
area expansion and albuminuria compared with wild-type diabetic
mice. These effects are associated with an upregulation of proﬁbrotic,
proinﬂammatory, and proapoptotic pathways in glomeruli [85]. By
contrast, treatment of db/db mice with type 2 diabetes with the PPARα
agonist fenoﬁbrate reduces urinary albumin excretion, glomerular
mesangial expansion, hyperglycemia, and insulin resistance [86]. A
renal protective effect of PPARα activation has also been documented in
animal models with nephropathy induced by type 1 diabetes mellitus
[87–89]. Administration of PPARα agonists also has beneﬁcial effects in
humans with diabetic nephropathy. For example, administration of
bezaﬁbrate is renal protective in patients with diabetic nephropathy
caused by type 2 diabetes [90]. This renal protective effect is associated
with a reduction in urinary albumin excretion and in levels of circulating
lipids [90]. In the Fenoﬁbrate Intervention and Event Lowering in
Diabetes (FIELD) study, fenoﬁbrate administration was associated with
a signiﬁcant reduction in the rate at which albuminuria progresses in
patients with type 2 diabetes [91].
PPARα agonist may slow the progression of diabetic nephropathy
by several diverse mechanisms. Activation of PPARα may ameliorate
diabetic nephropathy by exerting beneﬁcial systemic effects, for
example, by reducing circulating levels of glucose, insulin and lipids.
PPARα activation may also exert renal-speciﬁc effects that mediate
renoprotection in diabetic nephropathy. Stimulation of fatty-acid β-
oxidation via activation of PPARα provides a potential mechanism by
which the lipid content of tissues could be reduced to prevent lipid
accumulation and lipotoxicity. However, studies to investigate
whether this mechanism takes place in the diabetic kidney have not
yet been performed. Studies on macrophage and lipid-loaded
mesangial cells suggest that PPARα activation can directly regulate
cholesterol homeostasis and foam-cell formation [92,93], processes
which have important roles in the development of lipotoxic effects
and inﬂammation in diabetic nephropathy. The anti-inﬂammatory
and antinitrosative effects of PPARα in animal models of diabetic
nephropathy [85,89] could relate to the ability of PPARα to inhibit the
activation of NFκB, an obligatory step in the synthesis of proin-
ﬂammatory cytokines and inducible nitric oxide synthase, a major
inducer of nitrosative stress. Whether PPARα has a role in reducing
oxidative stress induced by renal NADPH oxidase has not been
examined. A direct effect of PPARα in the kidney is supported by the
fact that the PPARα agonist fenoﬁbrate blocked the adhesion of
leukocytes to mesangial cells induced by high levels of glucose and
suppressed the expression of type I collagen, type IV collagen and
TGF-β in mesangial cells treated with high levels of glucose [85,86].
Taken together this evidence suggests that, in addition to their lipid-
lowering effects, PPARα agonists also have therapeutic potential in
preventing the progression of diabetic nephropathy.
4.2. Peroxisome-proliferator-associated receptor γ
The role of PPARγ agonists (glitazones) in preventing the develop-
ment and progression of diabetic nephropathy has been reported in
numerous studies. The administration of a glitazone was found to be
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these animals, troglitazone decreased urine protein excretion and
reducedbloodglucose, bloodpressure, plasma insulin, andplasma lipids
[94]. Since then, a beneﬁcial effect of glitazones on diabetic nephropathy
has been consistently reported for in animal models of both type 1 and
type 2 diabetes. In many of these studies, the reduction of albuminuria
induced by glitazones was accompanied by a reduction of glomerular
hyperﬁltration and prevention of glomerulosclerosis and tubulointer-
stitial ﬁbrosis [95].
Several clinical studies have examined the renal protective
properties of glitazones in patients with type 2 diabetes. In most
studies, glitazone treatment resulted in a signiﬁcant reduction in
albuminuria [95]. Glitazone treatment had a greater antiproteinuric
effect than other oral hypoglycemic agents, such as metformin and
glibenclamide, at doses that achieved of similar glycemic control
[95,96]. In addition one retrospective case-controlled study [97] and
one prospective study [98] have suggested that TZDs (glitazones)
slow the progression of renal disease in patients with type 2 diabetes
mellitus. Some adverse effects of long-term glitazone treatment have
been observed, including hepatitis, weight gain and ﬂuid retention
[99], which has led to the withdrawal of troglitazone, and increasing
warnings regarding rosiglitazone which has been associated with an
increased risk of heart failure.
As the PPARα agonist fenoﬁbrate decreased food intake and the
development of fat deposits induced by rosiglitazone in obese ob/ob
mice [100], combination treatment with agonists of PPARα and
PPARγ or treatment with a dual agonist of both receptors may reduce
adverse effects associated with PPARγ activators and induce a
synergistic beneﬁcial effect in preventing the development of diabetic
nephropathy. Although direct comparative studies of the effectiveness
of combination agonism versus dual agonism of PPARs have not been
performed, treatment with a PPARα/PPARγ dual agonist protected
db/db mice against glomerular and interstitial damage and improved
insulin resistance, glycemic control and lipid proﬁle [101].
The mechanisms by which PPARγ agonists modulate diabetic
nephropathy have been reviewed elsewhere [96]. Normalization of
hyperglycemia, hyperlipidemia and hypertension by glitazone treat-
ment may be important in preventing the renal complications of
diabetes. In addition, studies in animal models, in isolated glomeruli,
and in renal cell cultures also indicate that glitazones have direct
actions on renal cells. In mesangial cells and in proximal tubule cells,
PPARγ agonists have antiproliferative, antiﬁbrotic, and anti-inﬂam-
matory effects [96]. In animal models of type 2 diabetes, activation of
PPARγ activation prevents renal endothelial cell dysfunction and
podocyte injury, and inhibits activation of NFκB, the accumulation of
reactive oxygen species, and inﬁltration of macrophages in the kidney
[96,102]. Studies in mesangial cells suggest that PPARγ may regulate
renal lipid metabolism by activating the LXRα–ATP-binding cassette 1
pathway to facilitate cholesterol efﬂux, suggesting a possible
mechanism for our more recent observations [103].
4.3. Peroxisome-proliferator-associated receptor δ
To date no studies have investigated the role of PPARδ in diabetic
nephropathy, and no clinical studies have investigated the use of
PPARδ agonists. In the Akita and the OVE26 mouse models of type 1
diabetes, renal expression of PPARδ is greatly suppressed compared
with wild-type mice [11]. When exposed to oxidized lipids, which are
ubiquitously produced in the renal tubules of animal models of dia-
betic nephropathy, proximal tubular cells of obese, diabetic rats
showed suppression of PPARδ expression [104]. These data suggest a
potentially important role for PPARδ in diabetic nephropathy. In
mouse models of ischemia-induced renal injury, administration of a
synthetic PPARδ agonist was associated with strong renal protection
and a reduction in medullary necrosis, apoptosis, and inﬂammation
[105]. The role of PPARδ in ameliorating inﬂammation and regulatinglipid metabolism in animal models of disease such as ischemia-
induced injury suggests that PPARδ agonists may also confer renal
protection in diabetic nephropathy.
5. Estrogen receptors
Both estrogen receptor α and estrogen receptor β are found in the
kidney, although estrogen receptor α is the predominant isoform.
Estrogen receptor α and estrogen receptor β are expressed in
glomeruli and in isolated mesangial cells [106,107]. Immunohisto-
chemical studies have also identiﬁed the expression of estrogen
receptors on podocytes [108]. Estrogen receptor α is the dominant
estrogen receptor in terms of its effects, and the kidney is an organ
where the effects of estrogen receptor α are particularly prominent
[109]. The role of estrogen receptor β in the kidney is less clear
than that of estrogen receptor α, but it has been suggested to be a
dominant repressor of estrogen-receptor α function [110]. In addition
to their localization in the nucleus, estrogen receptors also localize to
the plasma membrane and discrete cytoplasmic organelles, such as
the mitochondria and the endoplasmic reticulum. In these extranu-
clear locations, these receptors may mediate rapid nongenomic
functions; for instance membrane-bound estrogen receptors can
associate with G protein leading to intracellular release of calcium,
cyclic AMP generation, and kinase activation [111].
The connection between estrogen-receptor activity and diabetic
nephropathy has emerged from clinical studies and animal studies,
which have shown reduced levels of plasma estradiol and dysregula-
tion of estrogen-receptor signaling in diabetic kidneys [112]. Pre-
menopausal, nondiabetic women are known to have a reduced risk of
renal disease compared with age-matched, nondiabetic men [112].
However, the presence of diabetes diminishes the protective effect of
female gender so that diabetic women develop diabetic renal disease
at levels generally equivalent to those of their diabetic male coun-
terparts [113,114]. Numerous studies have suggested that estrogen
receptors may have a role in the loss of female-sex renoprotection in
patients with diabetes [112]. In support of this hypothesis, adminis-
tration of estradiol or other selective modulators of the estrogen
receptors has been found to attenuate the progression of diabetic
nephropathy in patients with this condition and in animal models of
the disease, as shown by the reduction of proteinuria, glomerulo-
sclerosis, and tubulointerstitial ﬁbrosis. In the kidney, estrogen
receptor signaling takes place in glomerular mesangial cells, endo-
thelial cells, and podocytes. In these cells, estrogen receptor activation
inhibits cell proliferation, decreases TGF-β expression, decreases
extracellular matrix accumulation, increases activity of endothelial
nitric oxide synthase, and increases expression of VEGF [112,115,116].
Additional studies are warranted to clarify the role of the estrogen
receptors in the regulation of inﬂammation and lipid metabolism, and
in the progression of diabetic nephropathy.
6. Estrogen-related receptors
The ERR subfamily of orphan nuclear receptors consists of three
members, ERRα, ERRβ and ERRγ. Although these receptors are
structurally homologous to estrogen receptors and bind estrogen
response elements, they are not activated by estrogens and their
physiological ligands are unknown. ERRs function as metabolic
regulators in all aspects of energy homeostasis, including lipid and
glucose metabolism and mitochondrial biogenesis [117]. All three
ERRs are expressed at moderate-to-high levels in the kidney, but
additional research is needed to determine the role of ERRs in this
organ. The transcriptional control of energy homeostasis by ERRs
strongly implicates their potential importance in slowing the
progression of diabetic nephropathy. Agonists with increased relative
selectivity for speciﬁc ERRs are becoming available and will help
identify the function of speciﬁc ERR isoforms [117].
Fig. 1. VDR, FXR, and PPARs modulate renal disease through multiple actions including
inhibition of proinﬂammatory cytokines, oxidative stress, proﬁbrotic growth factors,
and accumulation of lipids in the kidney.
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The provided evidence suggests that several nuclear receptors
especially the vitamin D receptor (VDR), farnesoid X receptor (FXR),
and peroxisome-proliferator-associated receptors (PPARs) through
their multiple actions in regulating lipid and energy metabolism,
inﬂammation, oxidative stress and ﬁbrosis exhibit a great potential in
preventing the progression of diabetic nephropathy (Fig. 1).
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